Palmitoylethanolamide

• Palmitoylethanolamide(PEAAlfa mai karɓa mai karɓa na peroxisome-activated proliferator (PPAR-�) ligand wanda ke yin aikin anti-mai kumburi, analgesic, da neuroprotective ayyuka, don maganin ciwon kumburi, musamman masu alaƙa da ciwo na kullum, glaucoma da ciwon sukari na retinopathy.
  • Tsarin (s) na aikin PEA ya ƙunshi tasirin sa akan mai karɓar mai karɓar PPARA (Gabrielsson et al., 2016).
  • Hakanan yana haifar da ƙwayoyin mast sel.cannabinoid mai karɓa nau'in 2 (CB2) -kamar masu karɓa na cannabinoid, tashoshi-potassium-tashoshi na ATP, tashoshin mai karɓa na wucin gadi (TRP), da kuma kappa B (NFkB) factor factor.
  • Yana iya rinjayar siginar endocannabinoid ta hanyar yin aiki a matsayin mai gasa ga endocannabinoid homologue anandamide (N-arachidonoylethanolamine).
• Tunanin farko ya kasance a cikin 1943 ta Coburn et al.a matsayin wani ɓangare na nazarin cututtukan cututtukan da aka mayar da hankali kan zazzabin rheumatic na yara, wanda abin da ya faru ya fi girma a cikin waɗannan yaran da ke cin abinci mai ƙarancin ƙwai.
  • Wadannan masu binciken sun lura cewa an rage abin da ya faru a cikin yara da ake ciyar da ƙwayar kwai, kuma daga bisani sun nuna kayan anti-anaphylactic a cikin aladun Guinea tare da tsantsa daga ruwan kwai.
• 1957 Kuehl Jr. da abokan aiki sun ba da rahoton cewa sun yi nasarar ware wani abu mai hana kumburi daga waken soya.Sun keɓance mahallin kuma daga ɓangaren phospholipid na gwaiwar kwai da kuma abincin gyada da aka ciro hexane.
  • Hydrolysis na PEA ya haifar da palmitic acid da ethanolamine kuma don haka an gano fili a matsayinN(2-hydroxyethyl) - palmitamide (Kepple Hesselink et al., 2013).

 

Jadawalin Yawo na Semi-synthesize Palmitoylethanolamide

 

 

 

 

 

 

 

Mass Spectra (ESI-MS: m/z 300(M+H+) da Nuclear Magnetic Resonance (NMR) na PEA

 

 

Kimiyyar Abinci & Abinci DOI 10.1002/fsn3.392

Tsaro na micronized palmitoylethanolamide (microPEA): rashin guba da yuwuwar genotoxic

 

• Palmitoylethanolamide (PEA) wani fatty acid amide ne na halitta da ake samu a cikin abinci iri-iri, wanda aka fara gano shi cikin gwaiwar kwai.
• MicroPEA na ƙayyadaddun girman barbashi (0.5-10μm) an kimanta don mutagenicity aSalmonella typhimurium,don clastogenicity/neuploidy a cikin ƙwayoyin lymphocytes na ɗan adam na al'ada, da kuma gaɗaɗɗen ƙwayar rodent mai ƙarfi a cikin bera, bin daidaitattun ka'idodin gwajin OECD, daidai da Kyawun Ayyukan Laboratory (GLP).
• PEA ba ta haifar da maye gurbi ba a cikin gwajin ƙwayoyin cuta ta amfani da nau'ikan TA1535, TA97a, TA98, TA100, da TA102, tare da ko ba tare da kunnawa na rayuwa ba, a cikin haɗawar farantin karfe ko hanyoyin preincubation na ruwa.Hakanan, PEA ba ta haifar da tasirin genotoxic a cikin sel ɗan adam da aka bi da su don 3 ko 24 h ba tare da kunnawa na rayuwa ba, ko don 3 h tare da kunnawa na rayuwa.
• An gano PEA tana da LD50 mafi girma fiye da iyakacin 2000 mg/kg nauyi na jiki (bw), ta amfani da OECD Acute Oral Up and Down Procedure.Matsakaicin binciken binciken guba na baka na kwanaki 90 sun dogara ne akan sakamakon binciken farko na kwanaki 14, wato, 250, 500, da 1000 mg/kg bw/rana.
• Matsayin Babu Tasiri (NOEL) a cikin duka karatun na yau da kullun shine mafi girman adadin da aka gwada.

Br J Clin Pharmacol. 2016 Oktoba; 82 (4): 932-42.

Palmitoylethanolamide don maganin ciwo: pharmacokinetics, aminci da inganci

• Gwaje-gwaje na asibiti goma sha shida, rahotanni na shari'a guda shida / nazarin matukin jirgi da meta-bincike na PEA a matsayin analgesic an buga su a cikin wallafe-wallafe.
  • Don lokutan jiyya har zuwa kwanaki 49, bayanan asibiti na yanzu suna jayayya da mummunan halayen miyagun ƙwayoyi (ADRs) a wani lamari na

 

• Don maganin da ke daɗe fiye da kwanaki 60, adadin marasa lafiya bai isa ba don kawar da mitar ADRs na ƙasa da 1/100.
• Gwajin gwaje-gwajen asibiti guda shida da aka buga suna da ingantattun inganci.Gabatar da bayanai ba tare da bayanai kan yada bayanai da rashin bayar da rahoto ba a wasu lokuta banda ma'aunin karshe na daga cikin batutuwan da aka gano.
• Bugu da ari, babu wani kwatancen kai-da-kai na asibiti na unmicronized vs. micronized formulations na PEA, don haka shaida na fifikon tsari ɗaya akan ɗayan a halin yanzu ya rasa.
• Duk da haka, bayanan asibiti da ke akwai suna goyan bayan hujjar cewa PEA tana da ayyukan analgesic da kuma ƙarfafa ƙarin nazarin wannan fili, musamman game da kwatancen kai-da-kai na ƙirar da ba a haɗa da micronized na PEA da kwatancen jiyya a halin yanzu ba.

Shaidar asibiti

• Na musammanAbinci don Maƙasudin Likita, a cikinMaganiof Na kullum Ciwo
• Micronized palmitoylethanolamide yana ragebayyanar cututtukaof ciwon neuropathica cikin ciwon sukari marasa lafiya
• Palmitoylethanolamide, a neutraceutical, in jijiya matsawa cututtuka: inganci kuma aminci in sciatic zafi da kuma carpal tunnel ciwo
• Palmitoylethanolamide in Fibromyalgia: Sakamako daga Mai yiwuwa kuma Na baya-bayan nan Na lura Nazarin
• Ultra-micronized palmitoylethanolamide: mai inganciadjuvant fardominCutar Parkinson

cuta.

• Na kullum ƙashin ƙugu zafi, inganci of rayuwa kuma jima'i lafiya of mata bi da tare da palmitoylethanolamide kuma α-lipoic acid
• Bazuwar na asibiti gwaji: da analgesic kaddarorin of abin da ake ci karitare da palmitoylethanolamide da polydatin a cikihanji mai ban haushi ciwo.
• Co-ultramicronized Palmitoylethanolamide/Luteolin in da Magani of Kwakwalwa Ischemia: daga Rodent to

Mutum

• Palmitoylethanolamide, a Halitta Retinoprotectant: Nasa Putative Dace domin da Maganiof Glaucomada masu ciwon suga Maganin ciwon ido
• N-palmitoylethanolamine kuma N-acetylethanolamine su ne tasiri in asteatotic eczema: sakamako of wani bazuwar, makafi biyu, binciken sarrafawa a cikin 60 marasa lafiya

 

 

 

 

 

 

 

 

 

 

Likitan Ciwo. 2016 Fabrairu; 19 (2): 11-24.

Palmitoylethanolamide, Abinci na Musamman don Maƙasudin Likita, a cikin Maganin Ciwo na Tsawon Lokaci: Ƙididdigar Meta-Bincike.

 

• BAYANI: Wani shaida mai girma yana nuna cewa neuroinflammation, wanda ke da alaƙa da shigar da ƙwayoyin rigakafi, kunna ƙwayoyin mast da ƙwayoyin glial, da kuma samar da masu shiga tsakani a cikin sassan jiki da na tsakiya, yana da muhimmiyar rawa a cikin shigarwa da kuma kula da na kullum. zafi.Wadannan binciken sun goyi bayan ra'ayi cewa sabon damar warkewa don ciwo na kullum zai iya dogara ne akan masu maganin kumburi da masu magance matsalolin da ke aiki akan ƙwayoyin rigakafi, musamman mast sel da glia, don ragewa ko kawar da neuroinflammation.

Daga cikin masu hana kumburi da masu sasantawa na lipid, palmitoylethanolamide (PEA) an ba da rahoton zuwa saukar da kunna mast cell da sarrafa halayen glial cell.

• MANUFOFI:Manufar wannan binciken shine don yin nazarin meta-bincike don kimanta inganci da amincin micronized da ultra-micronizedpalmitoylethanolamide (PEA) akan tsananin zafi a cikin marasa lafiya da ke fama da ciwo na yau da kullun da / ko ciwon neuropathic.
• NAZARITSIRA:Binciken bayanan da aka tattara wanda ya ƙunshi makafi biyu, sarrafawa, da gwajin gwaji na asibiti.
• HANYOYI:An zaɓi gwajin makafi sau biyu, sarrafawa, da buɗaɗɗen alamar gwaji na asibiti tare da tuntuɓar PubMed, Google Scholar, da bayanan bayanai na Cochrane, da kuma abubuwan da suka shafi tarurrukan neuroscience.An yi amfani da sharuddan ciwo na kullum, ciwon neuropathic, da kuma micronized da ultra-micronized PEA don bincike.Sharuɗɗan zaɓin sun haɗa da samun wadataccen bayanai da daidaitawa tsakanin kayan aikin da ake amfani da su don tantancewa da tantance tsananin zafi.An tattara ɗanyen bayanan da mawallafa suka samu a cikin rumbun adana bayanai guda ɗaya kuma Model ɗin Haɗaɗɗen Layin Layi ya yi nazari.Canje-canje a cikin jin zafi a tsawon lokaci, wanda aka auna ta hanyar kayan aiki masu kama da juna, an kuma kimanta su ta hanyar bincike na baya-bayan nan na layi da kuma ƙididdigar Kaplan-Meier.An haɗa karatun goma sha biyu a cikin ƙididdigar ƙididdiga, 3 daga cikinsu sun kasance gwaje-gwajen makafi sau biyu idan aka kwatanta masu kwatanta aiki vs placebo, 2 gwaje-gwajen buɗaɗɗen lakabi vs daidaitattun hanyoyin kwantar da hankali, kuma 7 sun kasance gwaje-gwajen alamar ba tare da masu kwatanta ba.
• Sakamako:Sakamako ya nuna cewa PEA yana haifar da raguwar ci gaba mai tsanani na ciwo mai tsanani fiye da sarrafawa.Girman raguwa yayi daidai

Maki 1.04 kowane mako 2 tare da bambance-bambancen amsa na 35% wanda tsarin layi ya bayyana.Sabanin haka, a cikin ciwo na ƙungiyar kulawa, raguwa mai tsanani yana daidai da maki 0.20 kowane mako 2 tare da kawai 1% na jimlar bambance-bambancen da aka bayyana ta hanyar sake dawowa.Ƙididdigar Kaplan-Meier ya nuna alamar ciwo = 3 a cikin 81% na PEA da aka bi da marasa lafiya idan aka kwatanta da 40.9% kawai a cikin marasa lafiya na kulawa ta ranar 60 na jiyya.Abubuwan PEA sun kasance masu zaman kansu daga shekarun haƙuri ko jinsi, kuma basu da alaƙa da nau'in ciwo mai tsanani.

• IYAKA:Abin lura, munanan al'amuran da suka shafi PEA ba a yi rajista da/ko ba da rahoto a cikin kowane ɗayan karatun ba.
• KARSHE:Wadannan sakamakon sun tabbatar da cewa PEA na iya wakiltar wani abu mai ban sha'awa, sabon dabarun warkewa don gudanar da ciwo na kullum da ciwon neuropathic

hade da neuroinflammation.

Maganin Res Pain. 2014; 2014: 849623.

Micronized palmitoylethanolamide yana rage alamun ciwon neuropathic a cikin masu ciwon sukari.

• Binciken na yanzu ya kimanta tasiri na

micronized palmitoylethanolamide (PEA-m) magani a cikin rage raɗaɗin bayyanar cututtuka da masu ciwon sukari ke fuskanta tare da neuropathy na gefe.

• An gudanar da PEA-m (300 MG sau biyu a rana) ga masu ciwon sukari 30

fama da ciwon ciwon neuropathy mai raɗaɗi.

• Kafin fara jiyya, bayan kwanaki 30 da 60 an tantance sigogi masu zuwa: alamun raɗaɗi na ciwon sukari na jijiyoyin bugun jini ta amfani da kayan aikin allo na Michigan Neuropathy;tsananin alamun halayen ciwon neuropathic mai ciwon sukari ta jimlar Alamar Alamar;da kuma ƙarfin nau'i-nau'i daban-daban na ciwon neuropathic ta Ƙididdigar Ƙwararrun Ƙwararrun Ƙwararrun Ƙwararrun Neuropathic.An kuma yi gwaje-gwajen ilmin sinadarai na jini da na jini don kimanta kulawar rayuwa da aminci.
• Ƙididdigar ƙididdiga (ANOVA) ya nuna raguwa mai mahimmanci a cikin tsananin zafi (P <0.0001) da kuma alamun da ke da alaƙa (P <0.0001) wanda Michigan Neuropathy Screening kayan aiki ya kimanta, Total Symptom Score, da Neuropathic Pain Symptoms Inventory.
• Binciken Hematological da fitsari bai bayyana wani canje-canjen da ke da alaƙa da jiyya na PEA-m ba, kuma ba a ba da rahoton wani mummunan lamari ba.
• Waɗannan sakamakon suna ba da shawarar cewa za a iya ɗaukar PEA-m a matsayin sabon magani mai ban sha'awa kuma mai jurewa don alamun bayyanar cututtukan da ke fama da masu ciwon sukari waɗanda ke fama da neuropathy na gefe.

J Pain Res. 2015 Oktoba 23;8:729-34.

Palmitoylethanolamide, wani neutraceutical, a cikin cututtukan cututtuka na jijiyoyi: inganci da aminci a cikin ciwon sciatic da ciwo na rami na carpal.

 

 

• Anan mun bayyana sakamakon duk gwaje-gwaje na asibiti da ke kimanta inganci da aminci na PEA a cikin cututtukan cututtuka na jijiyoyi: ciwo na sciatic da zafi saboda ciwon ramin carpal, da kuma nazarin shaida na ainihi a cikin nau'i na jijiyoyi.
  • Gabaɗaya, an buga gwaje-gwaje na asibiti guda takwas a cikin irin waɗannan cututtukan tarko, kuma an haɗa marasa lafiya 1,366 a cikin waɗannan gwaje-gwajen.
  • A cikin mahimmanci guda ɗaya, makafi biyu, gwajin gwaji na placebo a cikin 636 sciatic ciwon marasa lafiya, adadin da ake buƙata don magancewa don isa 50% rage zafi idan aka kwatanta da asali shine 1.5 bayan 3 makonni na jiyya.
  • PEA ya tabbatar da cewa yana da inganci kuma mai aminci a cikin cututtukan cututtukan jijiyoyi, ba a bayyana mu'amalar miyagun ƙwayoyi ko illolin matsala ba.
  • Ya kamata a yi la'akari da PEA a matsayin sabon zaɓin magani mai aminci don cututtukan cututtukan jijiyoyi.
    • Tun da sau da yawa an tabbatar da pregabaline co-analgesic

don zama marasa tasiri a cikin ciwon sciatic a cikin gwajin haɓaka makafi biyu.

• Likitoci ba koyaushe suna sane da PEA azaman madadin dacewa da aminci ga opioids da haɗin gwiwar analgesics a cikin maganin ciwon neuropathic.

 

 

NNT na PEA don kaiwa 50%

rage zafi

 

PEA, palmitoylethanolamide;VAS, sikelin analog na gani;NNT, lambar da ake buƙata don magani

Pain Ther. 2015 Dec; 4 (2): 169-78.

Palmitoylethanolamide a cikin Fibromyalgia: Sakamako daga Nazarce-nazarce da Na Ci gaba.

 

(duloxetine + pregabalin)

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Rage yawan madaidaitan maki masu taushi

 

 

 

Rage yawan zafin ciwo ta ma'aunin VAS.

CNS Neurol Disord Drug Targets. 21 Maris 2017.

Ultra-micronized palmitoylethanolamide: ingantaccen magani ga cutar Parkinson.

BAYANI:Cutar Parkinson (PD) batu ne na ƙoƙarce-ƙoƙarce don haɓaka dabarun da ke rage ko dakatar da ci gaban cuta da nakasa.Shaidu masu mahimmanci suna nuna muhimmiyar rawa ga neuroinflammation a cikin mutuwar kwayar cutar dopaminergic.Ultramicronized palmitoylethanolamide (um-PEA) sananne ne don ikonsa na haɓaka ƙudurin kumburin neuroinflammation da aiwatar da neuroprotection.An tsara wannan binciken don tantance ingancin um-PEA a matsayin maganin adjuvant a cikin marasa lafiya tare da PD ci gaba.

HANYOYI:An haɗa marasa lafiya talatin PD masu karɓar levodopa a cikin binciken.An yi amfani da bita-Move Disorder Society/Unified Parkinson's Disease Rating Scale (MDS-UPDRS) tambayoyin don tantance alamun mota da marasa motsi.An gudanar da gwaje-gwaje na asibiti kafin da kuma bayan ƙara um-PEA (600 MG).MDS-UPDRS jimlar maki na sassan I, II, III, da IV an yi nazarinsu ta amfani da Tsarin Haɗaɗɗen Tsarin Layi na Gabaɗaya, sannan gwajin sa hannun Wilcoxon ya biyo baya don kimanta bambancin ma'aunin kowane abu tsakanin tushe da ƙarshen um-PEA. magani.

Sakamako:Ƙara um-PEA zuwa marasa lafiya na PD masu karɓar levodopa sun haifar da raguwa mai mahimmanci da ci gaba a cikin jimlar MDS-UPDRS (sassan I, II, III da IV).Ga kowane abu, ma'anar ma'auni tsakanin asali da ƙarshen jiyya na um-PEA ya nuna raguwa mai yawa a yawancin alamun marasa motsi da motsi.An rage yawan marasa lafiya da alamun bayyanar cututtuka a basal bayan shekara guda na maganin um-PEA.Babu ɗaya daga cikin mahalartan da ya ba da rahoton illolin da aka danganta ga ƙarin um-PEA.

KARSHE:um-PEA ya rage jinkirin ci gaban cuta da nakasa a cikin marasa lafiya na PD, yana ba da shawarar cewa um-PEA na iya zama ingantaccen magani na adjuvant ga PD.

Minerva Ginecol. 2015 Oktoba; 67 (5): 413-9.

Ciwon pelvic na yau da kullun, ingancin rayuwa da lafiyar jima'i na mata da aka yi wa palmitoylethanolamide da α-lipoic acid.

• Manufar wannan takarda ita ce kimanta tasirin ƙungiyar

tsakanin palmitoylethanolamide (PEA) da α-lipoic acid (LA) akan ingancin rayuwa (QoL) da aikin jima'i a cikin matan da ke fama da ciwon ƙwanƙwasa endometriosis.

• Mata 56 ne suka kafa rukunin binciken kuma an ba su PEA 300 MG da LA 300mg sau biyu a rana.
• Don ayyana ciwon ƙashin ƙugu mai alaƙa da endometriosis, an yi amfani da ma'aunin analog na gani (VAS).An yi amfani da Short Form-36 (SF-36), Ma'anar Ayyukan Jima'i na Mata (FSFI) da Matsalolin Matsalolin Jima'i (FSDS) don tantance QoL, aikin jima'i da matsalolin jima'i, bi da bi.Binciken ya haɗa da biyo baya uku a cikin watanni 3, 6 da 9.
• Babu canje-canje da aka lura a cikin ciwo, QoL da aikin jima'i a cikin watanni na 3rd (P = NS).Ta hanyar 6th da 9th watan, alamun ciwo (P <0.001) da duk nau'ikan QoL (P <0.001) sun inganta.Makin FSFI da FSDS ba su canza ba a bibiyar wata na 3 (P=ns).Akasin haka, a cikin watanni na 3rd da 9th sun inganta game da asali (P <0.001).
• Rage ci gaba na ciwon ciwo da aka ruwaito ta hanyar mata a kan lokacin jiyya na iya taimakawa wajen inganta QoL da jima'i na mata akan PEA da LA.

Arch Ital Urol Androl. 2017 Maris 31; 89 (1): 17-21.

Ingancin ƙungiyar palmitoylethanolamide da alpha-lipoic acid a cikin marasa lafiya tare da prostatitis na yau da kullun / ciwo mai zafi na pelvic na yau da kullun: Gwajin gwaji na asibiti.

• BAYANI:Prostatitis na yau da kullum / ciwo mai zafi na pelvic (CP / CPPS) wani yanayi ne mai rikitarwa, wanda ba shi da tabbas game da ilimin cututtuka da kuma ta hanyar mayar da martani ga jiyya.Ma'anar CP/CPPS ya haɗa da ciwon genitourinary tare da ko ba tare da bayyanar cututtuka ba tare da rashin kwayoyin cutar uropathogenic, kamar yadda aka gano ta daidaitattun hanyoyin microbiological, ko wani dalili mai ganewa kamar malignancy.An yi la'akari da ingancin hanyoyin kwantar da hankali na likita daban-daban, a cikin nazarin asibiti, amma shaida ta rasa ko kuma ta bambanta.Mun kwatanta Serenoa Repens a monotherapy tare da Palmitoylethanolamide (PEA) a hade tare da Alpha-lipoic acid (ALA) kuma mun kimanta ingancin waɗannan jiyya a cikin marasa lafiya tare da CP/CPPS.
• HANYOYI:Mun gudanar da gwajin bazuwar, makafi ɗaya.44 marasa lafiya da aka gano tare da CP/CPPS (ma'anar shekaru

41.32 ± 1.686 shekaru) an ba da izini ga magani tare da Palmitoylethanolamide 300 MG da Alpha-lipoic acid 300 mg (Peanase®), ko Serenoa Repens a 320 MG.Tambayoyi uku (NIH-CPSI, IPSS da IIEF5) an gudanar da su a asali kuma bayan makonni 12 na jiyya a kowace ƙungiya.

• Sakamako:Jiyya na mako 12 tare da Peanase ya inganta ƙimar IPSS sosai idan aka kwatanta da daidai lokacin jiyya tare da Serenoa Repens, kuma an rage makin NIH-CPSI sosai.An lura da irin wannan sakamako a cikin mabambantan NIH-CPSI da aka rushe.Duk da haka, irin wannan magani bai haifar da gagarumin ci gaba na IIEF5 ba.Dukansu jiyya ba su haifar da tasirin da ba a so ba.
• KARSHE: Sakamakon yanzu yana rubuta ingancin ƙungiyar Palmitoylethanolamide (PEA) da Alpha-lipoic acid (ALA) waɗanda aka gudanar na makonni 12 don kula da marasa lafiya tare da CP/CPPS, idan aka kwatanta da Serenoa Repens monotherapy.

Aliment Pharmacol Ther. Fabrairu 6, 2017.

Randomized asibiti gwaji: da analgesic Properties naabin da ake ci kari

tare da palmitoylethanolamide da polydatin a cikin rashin jin daɗi na hanji.

 

• BAYANI:Kunna rigakafi na hanji yana shiga cikin ciwon hanji mai ban tsoro (IBS) pathophysiology.Duk da yake yawancin hanyoyin abinci a cikin IBS sun haɗa da guje wa abinci, akwai ƙarancin alamu akan ƙarin abinci.Palmithoylethanolamide, tsarin da ke da alaƙa da endocannabinoid anandamide, da polydatin sune mahadi na abinci waɗanda ke aiki tare don rage kunnawar mast cell.
• Manufar:Don tantance tasirin mast cell count da ingancin palmithoylethanolamide / polydatin a cikin marasa lafiya tare da IBS.
• HANYOYI:Mun gudanar da wani matukin jirgi, 12-mako, bazuwar, makafi biyu, mai sarrafa wuribo, nazarin cibiyar da yawa yana kimanta tasirin palmithoylethanolamide / polydatin 200 mg / 20 mg ko placebo bd akan ƙananan kunnawa na rigakafi, tsarin endocannabinoid da alamun bayyanar cututtuka a cikin marasa lafiya na IBS. .Samfurori na biopsy, waɗanda aka samu a ziyarar nunawa da kuma ƙarshen binciken, an bincika su ta hanyar immunohistochemistry, immunoassay mai alaƙa da enzyme, chromatography na ruwa da lalata Western.
• Sakamako:Jimillar marasa lafiya 54 tare da IBS da 12 masu kula da lafiya sun yi rajista daga cibiyoyin Turai biyar.Idan aka kwatanta da sarrafawa, marasa lafiya na IBS sun nuna ƙidayar ƙwayar mucosal mast cell (3.2 ± 1.3 vs. 5.3 ± 2.7%,

P = 0.013), rage yawan fatty acid amide oleoylethanolamide (12.7 ± 9.8 vs. 45.8 ± 55.6 pmol / mg, P = 0.002) da kuma ƙara yawan maganganun cannabinoid mai karɓa 2 (0.7 ± 0.1 vs. 1.0 ± 0.8, P2).Maganin bai canza bayanin martabar IBS ba sosai, gami da ƙididdigar mast cell.Idan aka kwatanta da placebo, palmithoylethanolamide/polydatin ya inganta tsananin ciwon ciki (P <0.05).

• KARSHE:Alamar sakamako mai mahimmanci na kari na palmithoylethanolamide / polydatin akan ciwon ciki a cikin marasa lafiya tare da IBS yana nuna cewa wannan wata hanya ce ta dabi'a don kula da ciwo a cikin wannan yanayin.Ana buƙatar ƙarin karatu yanzu don bayyana tsarin aikin palmithoylethanolamide / polydatin a cikin IBS.Lambar ClinicalTrials.gov,Saukewa: NCT01370720.

Transl Stroke Res. 2016 Feb; 7 (1): 54-69.

Co-ultramicronized Palmitoylethanolamide/Luteolin a cikin Maganin Cerebral Ischemia: daga Rodent zuwa Mutum.

 

 

 

An yi wa marasa lafiya Glialia® na tsawon kwanaki 60.

Ƙimar Barthel sun kasance 26.6 ± 1.69, 48.3 ± 1.91, da 60.5 ± 1.95 a T0 (242)

marasa lafiya), T30 (marasa lafiya 229), da T60 (218

marasa lafiya), bi da bi.

Akwai babban bambanci a cikin haɓakawa tsakanin T0 da T30 (***)p<0.0001) kuma tsakanin T0 da T60 (###)p<0.0001).Haka kuma, akwai bambanci sosai tsakanin T30 da T60 (p<0.0001).

Majinyatan mata sun nuna ƙananan maki fiye da maza, kuma nakasa ya fi muni a cikin marasa lafiya

Drug Des Devel Ther. 2016 Satumba 27; 10: 3133-3141.

Resolvins da aliamides: lipid autacoids a cikin ophthalmology - wane alkawari suke riƙe?

• Resolvins (Rvs) wani nau'in labari ne nakwayoyin endogenous na lipid(autacoids) tare da kaddarorin immunomodulating masu ƙarfi, waɗanda ke tsara lokacin ƙuduri na amsawar rigakafi mai aiki.
  • Waɗannan abubuwan daidaitawa ana samar da su a cikin gida, suna yin tasiri ga aikin sel da/ko kyallen takarda, waɗanda aka samar akan buƙata kuma daga baya suna daidaita su cikin sel ɗaya da/ko kyallen takarda.
  • Autacoid pharmacology, ci gaba a cikin 1970s, autacoid kwayoyi ko dai jikin-nasu mahadi da kansu ko precursors ko wasu abubuwan da aka samu daga gare ta, zai fi dacewa bisa sauki sunadarai, kamar 5- hydroxytryptophan, precursor for serotonin.
  • Babban aikin autacoids na waɗannan azuzuwan shine hana haɓakar ƙwayoyin cuta na rigakafi don haka yana aiki kamar siginar “tsayawa” a cikin hanyoyin kumburi in ba haka ba ya zama cututtukan cuta.
    • A cikin 1993, mai ba da lambar yabo ta Nobel Rita Levi-Montalcini (1909-2012) ta ƙirƙira kalmar "aliamides" don irin waɗannan mahadi, yayin aiki akan hanawa da daidaita rawar palmitoylethanolamide (PEA) a cikin ƙwayoyin mast ɗin wuce gona da iri.
    • An samo manufar aliamides daga gajartaALIA: kumburin gida autacoid mai adawa.
    • Kalmar ta sami hanyar shiga cikin filinN-acetylethanolamides autacoids, irin su PEA, ko da yake Levi-Montalcini ya bayyana "aliamide" a matsayin ra'ayi na kwantena don duk masu hana lipid da -modulating matsakanci.Wannan zai kuma haɗa da Rvs, protectins, da maresins.
    • Rvs sune metabolites na polyunsaturated ω-3 fatty acid: eicosapentaenoic acid (EPA), docosahexaenoic acid (DHA), da docosapentaenoic acid (DPA).
      • Metabolites na EPA ana kiran su E Rvs (RvEs), na DHA ana kiran su D Rvs (RvDs), na DPA kuma ana kiran su Rvs D.

(RvDsn-3DPA) da Rvs T (RvTs).

• Abubuwan kariya da maresin an samo su daga ω-3 fatty acid DHA.

J Ophthalmol. 2015; 2015: 430596.

Palmitoylethanolamide, Mai Maganin Gyaran Halitta: Mahimmancinsa na Matsala don Maganin Glaucoma da Ciwon Ciwon Ciwon Jiki.

 

Ciwon gabobin jiki barazana ce ga gani, kuma glaucoma da ciwon suga sune manyan abubuwan da ke haifar da lalacewar ƙwayoyin ido.Bayanan da aka yi kwanan nan sun nuna wata hanya ta pathogenetic na kowa don cututtuka guda biyu, bisa ga kumburi na kullum.

An kimanta PEA don glaucoma, ciwon sukari na retinopathy, da uveitis, jihohin cututtukan da suka danganci kumburi na kullum, cututtuka na numfashi, da cututtuka daban-daban na ciwo a cikin wasu gwaje-gwajen asibiti tun daga 70s na 20th karni.

An gwada PEA a cikin aƙalla 9 makafi mai sarrafa wuribo biyu, daga cikinsu akwai binciken biyu a cikin glaucoma, kuma an gano cewa yana da aminci da tasiri har zuwa 1.8 g / rana, tare da kyakkyawar jurewa.Don haka PEA tana da alƙawari a cikin maganin yawancin cututtukan retinopathies.

Ana samun PEA azaman ƙarin abinci (PeaPure) kuma azaman abincin abinci don dalilai na likita a Italiya (Normast, PeaVera, da Visimast).

Ana sanar da waɗannan samfuran a Italiya don tallafin abinci mai gina jiki a cikin glaucoma da neuroinflammation.Mun tattauna PEA a matsayin mai sanya kumburi mai kumburi da kuma maganin retinoprotectant a cikin maganin retinopathies, musamman masu alaƙa da glaucoma da ciwon sukari.

 

 

 

 

 

 

 

 

 

 

Makasudin kwayoyin halitta daban-daban na PEA.PPAR: peroxisome proliferator kunna mai karɓa;GPR-55: 119-marayu G-protein haɗe-haɗe masu karɓa;CCL: ligand chemokine;COX: cyclooxygenase;iNOS: inducible nitric oxide synthase;TRPV: mai karɓar mai karɓa na wucin gadi m tashar tashar cation subfamily V;IL: interleukin;Kv1.5,4.3: potassium ƙarfin lantarki gated tashoshi;Toll-4 R: mai karɓa kamar mai karɓa.

Clin Interv tsufa. 2014 Jul 17;9:1163-9.

N-palmitoylethanolamine da N-acetylethanolamine suna da tasiri a cikin eczema asteatotic: sakamakon bazuwar, makafi biyu, binciken sarrafawa a cikin marasa lafiya 60.

 

 

 

• BAYANI:Asteatotic eczema (AE) yana da ƙaiƙayi, bushe, m, da fatar fata.Jiyya na AE sune galibi abubuwan motsa jiki, yawanci suna ɗauke da urea, lactic acid, ko gishirin lactate.N-palmitoylethanolamine (PEA) da N-acetylethanolamine (AEA) dukkansu lipids ne na ƙarshe waɗanda aka yi amfani da su azaman kayan aikin warkewa na zamani don maganin cututtukan fata da yawa.Manufar wannan binciken shine don kwatanta abin da ake kira PEA / AEA tare da maganin gargajiya na gargajiya a cikin maganin AE.
• HANYOYI:An gudanar da gwajin gwaji na monocentric, bazuwar, makafi biyu, gwajin kwatancen a cikin marasa lafiya na 60 AE don kimantawa da kwatanta tasirin abubuwan da ke tattare da su.Matsayin bushewar fata a cikin batutuwa ya bambanta daga mai laushi zuwa matsakaici.An gwada aikin shingen fata na batutuwan da matakin fahimta na yanzu na tsawon kwanaki 28 ta hanyar maki na asibiti da fasahar kere kere.
• Sakamako:Sakamakon ya nuna cewa, ko da yake an inganta wasu al'amura a cikin ƙungiyoyi biyu, ƙungiyar ta amfani da emollient dauke da PEA / AEA ya gabatar da mafi kyawun canjin fata a cikin capacitance.Duk da haka, mafi kyawun binciken shine ikon PEA / AEA emollient don ƙara ƙimar 5 Hz na yanzu zuwa matakin al'ada bayan kwanakin 7, tare da babban bambanci tsakanin dabi'u a asali da kuma bayan kwanaki 14.Matsakaicin tsinkaye na yanzu na 5 Hz yana da inganci kuma yana da alaƙa da mahimmanci tare da hydration na fata kuma yana da alaƙa da rashin daidaituwa tare da asarar ruwa ta transepidermal a cikin rukunin emollient na PEA/AEA.
• KARSHE: Idan aka kwatanta da abubuwan motsa jiki na al'ada, aikace-aikacen yau da kullun na emollient na PEA/AEA na iya inganta duka ayyukan fata masu wucewa da aiki lokaci guda.

 

 

Canje-canje a cikin hydration na saman fata sama da kwanaki 28

 

 

Idan aka kwatanta da na gargajiya emollient, PEA / AEA emollient na iya sarrafa duka biyu "m" da "ayyukan" ayyuka na fata lokaci guda, ciki har da farfadowar fata da maido da lamellae na lipid, jin daɗin fata, da ƙwarewar rigakafi.

 

Yadda PEA ke aiki

• Tsarin (s) na aikinPEA ya ƙunshiillarsa ga makaman nukiliyamai karɓaPPARA(Gabrielsson et al., 2016).
• Hakanan ya ƙunshi ƙwayoyin mast, cannabinoidmai karɓanau'in 2 (CB2)kamarcannabinoidmasu karɓa,ATP-m potassium-tashoshi, wucin gadimai karɓam (TRP) tashoshi, da makaman nukiliyadalilikapa B (NFkB).
• Ze iyatasiriendocannabinoid siginar ta yin aiki azaman gasasubstrate donendocannabinoid homologue anandamide (N-arachidonoylethanolamine).
• Gut-brain axis: Matsayin lipids a ciki tsarin kumburi, zafi da CNS cututtuka.

 

 

 

 

 

Curr Med Chem. 2017 Feb

16.

Gut-brain axis: Matsayin lipids a cikin tsarin kumburi, zafi da cututtukan CNS.

 

 

 

 

 

 

• Gut ɗin ɗan adam wani yanayi ne na anaerobic da aka haɗa tare da ƙaƙƙarfan microbiota iri-iri kuma mai ƙarfi, wanda sama da tiriliyan 100 microorganisms ke wakilta, gami da aƙalla nau'ikan nau'ikan nau'ikan 1000.
• Gano cewa wani nau'in ƙwayoyin cuta daban-daban na iya yin tasiri ga ɗabi'a da fahimta, kuma bi da bi tsarin juyayi na iya yin tasiri a kaikaice abun da ke ciki na microbiota, ya ba da gudummawa sosai don tabbatar da ingantaccen ra'ayi na axis-kwakwalwa.

 

• Wannan hasashe yana goyan bayan shaidu da yawa da ke nuna hanyoyin haɗin gwiwa, waɗanda suka haɗa da jijiyoyi mara kyau, tsarin rigakafi, yanayin axis na hypothalamic-pituitary-adrenal (HPA) da ƙwayoyin cuta da aka samu.

metabolites.

 

• Yawancin karatu sun mayar da hankali kan ƙaddamar da rawar da wannan axis a cikin kiwon lafiya da cututtuka, kama daga matsalolin da ke da alaka da damuwa irin su damuwa, damuwa da ciwo na hanji (IBS) zuwa cututtuka na neurodevelopmental, irin su autism, da kuma cututtuka na neurodegenerative, irin su Parkinson. Cuta, Cutar Alzheimer da dai sauransu.

 

• Dangane da wannan bangon, da kuma la'akari da dacewa da canjin yanayin yanayi tsakanin mai gida da microbiota, wannan bita ya mayar da hankali kan rawar da kuma shigar da lipids na bioactive, irin su dangin N-acylethanolamine (NAE) wanda manyan mambobin su ne N-arachidonoylethanolamine. (AEA), palmitoylethanolamide (PEA) da oleoilethanolamide (OEA), da gajeriyar sarkar fatty acid (SCFAs), irin su butyrate, na cikin babban rukuni na lipids na bioactive waɗanda ke iya daidaita tsarin na gefe da na tsakiya.

 

• An tabbatar da tasiri mai tasiri a cikin kumburi, ciwo mai tsanani da ciwo mai tsanani, kiba da cututtuka na tsakiya na tsakiya.An nuna yiwuwar alaƙa tsakanin waɗannan lipids da gut microbiota ta hanyoyi daban-daban.Lalle ne, tsarin tsarin tsarin ƙwayoyin cuta na musamman na iya rage ciwon ciki ta hanyar shiga cannabinoid mai karɓa na 1 a cikin bera;a gefe guda, PEA yana rage alamun kumburi a cikin samfurin murine na cututtukan cututtuka na huhu (IBD), kuma butyrate, wanda aka yi ta hanyar gut microbiota, yana da tasiri wajen rage kumburi da ciwo a cikin ciwon hanji mai banƙyama da kuma nau'in dabba na IBD.

 

• A cikin wannan bita, mun jadada dangantakar dake tsakanin kumburi, zafi, microbiota da lipids daban-daban, suna mai da hankali kan yuwuwar shigar da NAEs da SCFAs a cikin kwakwalwar gut-kwakwalwa da rawar da suke takawa a cikin cututtukan tsarin juyayi na tsakiya.

Tasirin palmitoylethanolamide (PEA) akan Akt/mTOR/p70S6K axis kunnawa da HIF-1a magana a cikin DSS-induced colitis da kuma ulcerative colitis.

 

 

 

PLoS Daya.2016;11 (5): e0156198.

 

 

Palmitoylethanolamide (PEA) yana hana angiogenesis mai alaƙa da colitis a cikin mice.(A) DSS-induced colitis ya haifar da karuwa mai yawa na Hb-abun ciki a cikin mucosa na colonic, PEA yana iya ragewa, a cikin yanayin da ya dogara da kashi, abun ciki na Hb a cikin ƙwayoyin colitis;wannan tasirin ya ci gaba a gaban PPARγ antagonist (GW9662) yayin da PPARA antagonist (MK866) ya soke shi.(B) Hotunan immunohistochemical da ke nuna furcin CD31 akan mucosa na mice ba a kula da su ba (panel 1), DSS-magance mice colonic mucosa (panel 2), DSS-mayar da mice colonic mucosa a gaban PEA (10 mg/Kg) kadai (panel) 3), PEA (10 mg/Kg) da MK866 10 mg/Kg (panel 4), da PEA (10 mg/Kg) da GW9662 1 mg/Kg (panel 5).Girman girman 20X;sikelin bar: 100μm.Jadawalin ya taƙaita ƙayyadaddun ƙayyadaddun ƙayyadaddun maganganun CD31 (%) akan mucosa na mice colonic a cikin ƙungiyoyin gwaji guda ɗaya, yana nuna raguwar maganganun CD31 a cikin mice colitic bayan gwamnatin PEA, ban da ƙungiyar kuma ana bi da su tare da antagonist na PPARA.

(C) Sakin VEGF ya haifar da karuwa a cikin berayen da DSS ke yi wa magani kuma an rage shi sosai ta hanyar PEA ta hanyar dogaro da PPARA.(D) Western blot bincike da

nazarin densitometric dangi (raka'o'in sabani da aka daidaita akan maganganun furotin β-actin) na VEGF-receptor (VEGF-R), yana nuna sakamako iri ɗaya zuwa sakin VEGF.Ana bayyana sakamako azaman ma'ana±SD.*p<0.05, **p<0.01 da ***p<0.001 sabanin berayen da DSS ke yiwa magani

PLoS Daya.2016;11 (5): e0156198.

Sci Rep. 2017 Maris 23; 7 (1): 375.

Palmitoylethanolamide yana haifar da canje-canje na microglia da ke hade da haɓaka ƙaura da ayyukan phagocytic: sa hannu na mai karɓar CB2.

 

• An nuna endogenous fatty acid amide palmitoylethanolamide (PEA) don aiwatar da ayyukan anti-mai kumburi musamman ta hanyar hana sakin ƙwayoyin cuta masu kumburi daga ƙwayoyin mast, monocytes da macrophages.Kunna kai tsaye na tsarin endocannabinoid (eCB) yana daga cikin hanyoyin aiwatar da ayyuka da yawa waɗanda aka ba da shawarar yin tasiri daban-daban na PEA a cikin vivo.
• A cikin wannan binciken, mun yi amfani da microglia na al'ada da macrophages na ɗan adam don kimanta ko PEA yana shafar siginar eCB.
• An samo PEA don ƙara yawan CB2 mRNA da furotin na furotin ta hanyar kunnawa mai karɓa-a (PPAR-α) mai kunnawa na peroxisome.
  • An nuna wannan sabon tsarin ƙa'idar tsarin halittar ta hanyar: (i)

Pharmacological PPAR-α magudi, (ii) PPAR-a mRNA shiru,

(iii) chromatin immunoprecipitation.

• Haka kuma, fallasa ga PEA ya haifar da sauye-sauyen yanayin halittar jiki da ke da alaƙa da yanayin yanayin phenotype na microglial, gami da haɓaka phagocytosis da ayyukan ƙaura.
• Abubuwan da muka gano suna ba da shawarar ƙa'ida ta kai tsaye ta microglial CB2R magana a matsayin sabon tsarin da zai yiwu wanda ke haifar da tasirin PEA.Ana iya bincika PEA azaman kayan aiki mai amfani don hanawa / magance alamun da ke hade da neuroinflammation a cikin cututtukan CNS.

 

 

 

 

 

 

 

 

Model na 2-AG metabolism da yuwuwar gudummawar sa ga ciwon bayan aiki.Enzymes wanda ke daidaita metabolism na 2-AG.2-AG metabolism yana faruwa da farko ta hanyar hydrolysis ta monoacylglycerol lipase (MAGL), samar da arachidonic acid, wanda daga baya ya canza zuwa eicosanoids ta COX da LOX enzymes.Bugu da kari, 2-AG za a iya metabolized cikin prostaglandin glycerol esters (PG-Gs) ta COX-2 da hydroperoxyeicosatetraenoic acid glycerol esters (HETE-Gs) ta LOX enzymes.

 

 

Ciwo 2015 Fabrairu; 156 (2): 341-7.

Pharmacol Res Perspect. 2017 Fabrairu 27; 5 (2): e00300.

Gidan anti-mai kumburi palmitoylethanolamide yana hana samar da prostaglandin da hydroxyeicosatetraenoic acid ta layin salula na macrophage.

 

Tasirin PEA akan matakan (A) PGD2;(B) PGE2;(C) 11-HATA;(D) 15-HATA;(E) 9-HODE da (F) 13-HODE in

LPS + IFNγKwayoyin RAW264.7 da aka bi da su.

Kwayoyin (2.5 × 105 kowace rijiya) an ƙara su zuwa faranti shida tare da LPS (0.1)μg/ml da kyau) da kuma INFγ (100 U/ml) da kuma al'ada a 37 ° C na 24 h.PEA (3μmol/L, P3;ko kuma 10μmol/L, P10) ko abin hawa an ƙara ko dai a farkon wannan lokacin al'ada ("24 h") ko na 30 min bayan LPS + INFγ lokacin shiryawa ("minti 30").

TheP dabi'u sun kasance daga ƙirar layi don manyan tasirin kawai (manyan layuka uku,ti = bangaren lokaci, tare da 30 min a matsayin ƙimar tunani) ko don samfurin ciki har da hulɗa (launi biyu na ƙasa), ƙididdiga ta amfani datRarraba da aka ƙayyade ta bootstrap tare da maye gurbin (10,000 iterations) na bayanai a ƙarƙashin hasashe mara kyau.Matsaloli masu yuwuwa da masu yuwuwa, masu tuta a cikin filayen Boxplot (Tukey), ana nuna su azaman triangles da murabba'i ja, bi da bi.An haɗa abubuwan da za a iya fitar da su a cikin ƙididdigar ƙididdiga, yayin da aka cire mai yuwuwar mai yiwuwa.Sandunan suna wakiltar ƙimar matsakaici bayan keɓance mai yuwuwar fita (n = 11-12).Domin 11-HETE, daP dabi'u ga dukkan saitin bayanai (watau ciki har da mai yuwuwar fita) sun kasance:ti, 0.87;P3, 0.86;P10, 0.0020;ti × P3, 0.83;ti x P10, 0.93.

 

CIN KWAS

 

• PEA a halin yanzu yana samuwa a duk duniya a cikin nau'i na kayan abinci na abinci, abinci na likitanci, da / ko abubuwan gina jiki a cikin nau'o'i daban-daban, tare da kuma ba tare da kayan haɓaka ba (Hesselink da Kopsky, 2015).
• A halin yanzu ana siyar da PEA don amfanin dabbobi (yanayin fata, Redonyl ™, wanda Innovet ke ƙera) kuma azaman sinadari mai gina jiki a cikin mutane (Normast ™ da Pelvilen ™, wanda Epitech ke ƙerawa; PeaPure ™, wanda JP Russel Science Ltd ya kera) a wasu ƙasashen Turai. (misali Italiya, Spain da Netherlands) (Gabrielsson et al., 2016).
• Hakanan wani nau'in kirim ne (Physiogel AI™, wanda Stiefel ya ƙera) wanda aka tallata don bushewar fata (Gabrielsson et al., 2016).
• Ultramicronized PEA an yi rajista azaman abinci don dalilai na musamman ta Ma'aikatar Lafiya ta Italiya kuma ba a lakafta shi don amfani da ciwon neuropathic (Andersen et al., 2015).
• Hukumar Abinci da Magunguna (FDA) ba ta yi nazarin amincin PEA a baya ba.Babu wasu ƙa'idodi a cikin Amurka da suka halatta amfani da PEA azaman ƙari na abinci ko abun GRAS.

 

 

FDA akan Abincin Abinci

• A Amurka, abinci na likitanci nau'in samfur ne na musamman wanda FDA ke tsara shi.

• A cikin Turai, irin wannan nau'in da ake kira "Abinci don Maƙasudin Likita na Musamman" (FSMPs) yana ƙarƙashin umarnin Abinci don Amfani na Musamman na Gina Jiki da Hukumar Tarayyar Turai (EC) ta tsara.
• A cikin 1988 FDA ta yi matakai don ƙarfafa haɓakar nau'in abinci na likitanci ta hanyar ba da samfuran samfuran magungunan marayu.
  • Waɗannan sauye-sauye na tsari suna rage farashi da lokacin da ke da alaƙa da kawo abinci na likitanci kasuwa, kamar yadda a da ana kula da abincin likitanci azaman magungunan magunguna.
  • Ba a buƙatar abinci na likita don yin bitar premarket ko amincewa ta FDA.Bugu da ƙari, an keɓe su daga buƙatun lakabi don da'awar lafiya da da'awar abun ciki na gina jiki a ƙarƙashin Dokar Lakabin Gina Jiki da Ilimi na 1990.
    • Ba kamar kayan abinci na abinci ba, waɗanda aka ƙuntata daga yin iƙirarin cuta kuma an yi niyya ga mutane masu lafiya, abincin likitanci an yi niyya ne don takamaiman adadin cutar.
    • Dole ne a goyi bayan da'awar cututtuka ta ingantacciyar shaidar kimiyya da ke tabbatar da nasarar sarrafa cutar.
    • Duk abubuwan da ake buƙata dole ne a yarda da kayan abinci ko kuma a rarraba su azaman GRAS.

 

FDA akan Abincin Abinci

 

• FDA ta Amurka ta ayyana abinci na likitanci a matsayin nau'in abubuwan da aka yi niyya don sarrafa tsarin abinci na asibiti na wani yanayi ko cuta.Takamaiman sharuɗɗan da ake buƙata don karɓar wannan sunan FDA sun haɗa da cewa dole ne samfurin ya kasance:
  • Abincin da aka keɓance na musamman don sha na baki ko na ciki;
  • Don kula da abinci na asibiti na takamaiman cuta ta likita, cuta ko yanayin rashin daidaituwa wanda akwai buƙatun abinci na musamman;
  • Anyi tare da Gabaɗaya Gane As Safe (GRAS) sinadaran;
  • Dangane da ƙa'idodin FDA waɗanda suka shafi lakabi, da'awar samfur da

masana'antu.

• A matsayin nau'in warkewa, abincin likitanci ya bambanta da duka magunguna da kari.
  • Dole ne alamomin sun haɗa da jumlar, "domin a yi amfani da su ƙarƙashin kulawar likita," kamar yadda ake samar da abinci na likitanci a ƙarƙashin ingantattun ayyukan masana'antu da kiyaye manyan ƙa'idodi.

Shin abincin likitanci shine babban yanayi na gaba na kayan abinci?

• Dama a cikin sashin abinci na likitanci suna girma;An kiyasta kasuwar ta kai dala biliyan 15, a cewarThebangoTitin Jarida.
• Manyan kamfanonin abinci, ciki har da Nestle da Hormel, suna yin saka hannun jari a R&D da layin samfur don biyan bukatun likita da abinci mai gina jiki.
  • Nestle ya gabatar da waniKasafin kudi dala miliyan 500 don tallafawa binciken abinci na likitanci ta hanyar 2021.
  • Dangane da kalubale, samun ilimin kimiyya daidai da samun amana ga sana'ar kiwon lafiya zai zama mahimmanci
    • Ya kamata masanan masana'anta su ci gaba da gudanar da bincike a kimiyyar likitanci kuma mai yiwuwa su haɗa tare da jami'o'in bincike don shiga, ko dai don tallafawa bincike ko don samun mahimman ilimi.

Misalai na musamman na kayan abinci na likitanci da aka kasuwa da kuma amfanin su

• Axona (caprylic triglyceride) -Cutar Alzheimer[5]
  • Banatrol Plus (banana flakes/Bimuno, galacto-oligosaccharide -gudawa[6]
  • Deplin (l-methylfolate) -bakin ciki[7]
  • Fosteum (genistein aglycone / citrated zinc bisglycinate / cholecalciferol)

-osteopenia kumaosteoporosis[8]

• Limbrel (flavocoxid) -osteoarthritis[9]
• Metanx (L-methylfolate calcium/pyridoxal 5′-phosphate/methylcobalamin) -ciwon sukari neuropathy[10]
• Theramine (l-arginine, 5-htp, histidine, l-glutamine) -myalgia[11]